BioAtla (BCAB)

Executive Summary

BioAtla is a clinical-stage biopharmaceutical company developing Conditionally Active Biologics (CAB), a novel class of antibodies engineered to activate selectively within the acidic and hypoxic tumor microenvironment. This innovative approach aims to improve the therapeutic index by reducing on-target, off-tumor toxicity, potentially enabling safer treatment of previously undruggable targets. The company is publicly traded (NASDAQ: BCAB) and has several ongoing clinical trials across multiple solid tumor indications, including non-small-cell lung cancer, ovarian cancer, and head and neck cancers. Key pipeline programs include BA3071 (CAB-CTLA-4) in combination with checkpoint inhibitors and pemetrexed for NSCLC/melanoma, and a durvalumab-based combination regimen for ovarian cancer. Near-term catalysts include data readouts from BA3071 combination trials expected in mid-2026 and from the ovarian cancer trial in late 2026. Additionally, the company may seek partnership opportunities to leverage its CAB platform. Given the promising technology but early stage, we assign a moderate conviction score.

Upcoming Catalysts (preview)

• Q3 2026Data readout from BA3071 combination trial (NCT05180799) in NSCLC/Melanoma60% success
• Q4 2026Data readout from durvalumab combination trial (NCT04918186) in Ovarian Cancer50% success
• TBDPotential partnership or licensing deal for CAB platform40% success